But DAPK promoter methylation had a similar frequency in the blood in GC and controls, these results suggested that promoter methylation of the ten tumor-related genes (p16, CDH1, RUNX3, MLH1, RASSF1A, p15, APC, GSTP1, Reprimo, and MGMT) may be potential biomarkers based-blood test for GC. This evidence concerns the gene CDKN2A and neoplasm.